Market Overview

Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences


SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at the following upcoming investor conferences:

  • 2019 Wells Fargo Securities Healthcare Conference, September 4-5, Boston
    • Thursday, September 5 at 10:20 am
  • H.C. Wainwright 21st Annual Global Healthcare Conference, September 9-10, New York City
    • Monday, September 9 at 3:50 pm

Live webcasts will be available in the investor section of the company's website: The webcasts also will be archived for 60 days following the presentations.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. NIDA, a division of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its licensee, Adapt Pharmaceuticals, now owned by Emergent BioSolutions Inc. For more information visit:

For Investor Relations and Media Inquiries:
Lisa Sher
Senior Director, Investor Relations and Communications
Opiant Pharmaceuticals, Inc.
(970) 987-2654

Dan Ferry
Managing Director
LifeSci Advisors, LLC
(617) 535-7746

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at